Scoop: As­cle­tis' NASH sub­sidiary scraps US PhII tri­al in fa­vor of Chi­na

Gan­nex Phar­ma, the NASH-fo­cused sub­sidiary of Chi­na’s As­cle­tis, has with­drawn a US-based Phase II tri­al orig­i­nal­ly slat­ed to be­gin in De­cem­ber 2023.

The biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER